AN1.XA - Anagenics Limited

Cboe AU - Cboe AU Real-time price. Currency in AUD

Anagenics Limited

55 Clarence Street
Suite 204 Level 2
Sydney, NSW 2000
61 2 9221 6830

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Matthew DudekChief Financial & Governance Officer636.27kN/AN/A
Mr. Scott Mitchell GreasleyCEO, MD & Exec. DirectorN/AN/AN/A
Mr. Dominic BurgChief Operating OfficerN/AN/AN/A
Dr. Graham RobertsonHead of R&DN/AN/AN/A
Mr. Lee Tamplin B.A.Company Sec.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Anagenics Limited operates as a health and beauty-tech company in Australia, New Zealand, Japan, and internationally. The company develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. It markets its products through various channels, including e-commerce, television shopping, wholesale pharmacy and salons, and cross border export markets. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.

Corporate governance

Anagenics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.